Anales de la RANM

273 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 RELEVANCIA DE LOS DEPÓSITOS DE GADOLINIO Frontera Valero L, et al. An RANM. 2024;141(03): 266 - 273 13. Le Fur M, Caravan P. The biological fate of ga- dolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics. 2019; 11(2): 240-254. 14. Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and options with ga- dolinium-based contrast agents in patients with CKD: a review. Am J Kidney Dis. 2021; 77(4): 517-528. 15. Van der Molen AJ, Quattrocchi CC, Mallio CA, Dekkers IA. Ten years of gadolinium retention and deposition: ESMRMB-GREC looks bac- kward and forward. Eur Radiol. 2024; 34: 600- 611. 16. Choi JW, Moon WJ. Gadolinium deposition in the brain: Current updates. Korean J Radiol. 2019; 20(1): 134-147. 17. Rasschaert M, Weller RO, Schroeder JA, Bro- chhausen C, Idée JM. Retention of gadolinium in brain parenchyma: Pathways for speciation, access, and distribution: a critical review. Invest Radiol. 2020; 55(5): 273-284. 18. Jynge P, Skjold AM, Falkmer U et al. MnDPDP: Contrast agent for imaging and protection of viable tissue. Contrast Media Mol Imaging. 2020; 2020: 3262835. 19. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the denta- te nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with in- creasing cumulative dose of a gadolinium-ba- sed contrast material. Radiology. 2014; 270(3): 834-841. 20. Chen JW. Does brain gadolinium deposition have clinical consequence? Lessons from ani- mal studies. Radiology. 2021; 301(2): 417-419. 21. Quattrocchi CC, Ramalho J, van der Molen AJ et al. Standardized assessment of the signal in- tensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium(GREC) Task Force position statement. Eur Radiol. 2019; 29: 3959-3967. 22. Daldrup-Link HE, Theruvath AJ, Rashidi A et al. How to stop using gadolinium chelates for magnetic resonance imaging: Clinical-trans- lational experiences with ferumoxytol. Pediatr Radiol. 2022; 52: 354-366. 23. Minaeva O, Hua N, Franz ES et al. Nonhomoge- neous gadolinium retention in the cerebral cor- tex after intravenous administration of gadoli- nium-based contrast agent in rats and humans. Radiology. 2020; 294(2): 377-385. 24. Ray RZ, Eduard M, John HF et al. Histological features of gadolinium deposition in the brain: a case report. Acta Neuropathol. 2020; 140(2): 241-244. 25. Scaravilli A, Tranfa M, Pontillo G et al. MR imaging signs of gadolinium retention are not associated with long-term motor and cogniti- ve outcomes in multiple sclerosis. AJNR Am J Neuroradiol. 2023; 44(4): 396-402. 26. McDonald RJ, McDonald JS, Kallmes DF et al. Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Ra- diology. 2017; 285(2): 546-554. 27. Iacobellis F, Di Serafino M, Russo C et al. Safe and informed use of gadolinium-based contrast agent in body magnetic resonance imaging: Where we were and where we are. J Clin Med. 2024; 13(8): 2193. 28. Quattrocchi CC, van der Molen AJ. Gadolinium retention in the body and brain: Is it time for an international joint research effort? Radiology. 2017; 282(1): 12-16. 29. Costa AF, van der Pol CB, Maralani PJ et al. Ga- dolinium deposition in the brain: a systematic review of existing guidelines and policy sta- tement issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2018; 69(4): 373-382. 30. Lange S, Mędrzycka-Dąbrowska W, Zorena K et al. Nephrogenic systemic fibrosis as a com- plication after gadolinium-containing contrast agents: a rapid review. Int J Environ Res Public Health. 2021; 18(6): 3000. 31. Davenport MS. Virtual elimination of nephro- genic systemic fibrosis: a medical success story with a small asterisk. Radiology. 2019; 292(2): 387-389. 32. U.S. Food and Drug Administration. La FDA advierte que los medios de contraste basados en gadolinio (MCBG) se depositan en el cuerpo y exige una nueva clase de advertencias [Inter- net]. FDA; 2023. 33. European Medicines Agency. Gadolinium ar- ticle 31 referral: EMA’s final opinion confirms restrictions on the use of linear gadolinium agents in body scans [Internet]. Available from: https://www.ema.europa.eu/en/documents/re- ferral/gadolinium-article-31-referra l-emas-fi- nal-opinion-confirms-restrictions-use-linear- gadolinium-agents-body-s cans_en.pdf Si desea citar nuestro artículo: Frontera Valero L, Hodgert A, Castro Vidal D, Bellido Padilla M, Pardo Maiza J, Centelles-Oria MM, Poveda Andrés JL, Martí-Bon- matí L. Retos para entender la relevancia del depósito de gado- linio tras su administración en resonancia magnética. An RANM. 2024;141(03): 266– 273. DOI: 10.32440/ar.2024.141.03. rev07